Psyence Biomedical (PBM) Competitors

$5.01 -0.03 (-0.50%)

As of 02:06 PM Eastern

PBM vs. AEON, XCUR, KTTA, QNCX, and LPCN

Should you buy Psyence Biomedical stock or one of its competitors? MarketBeat compares Psyence Biomedical with other companies and stocks that may be similar based on industry, sector, market capitalization, business model, investor interest, or shared news coverage. Companies and stocks commonly compared with Psyence Biomedical include AEON Biopharma (AEON), Exicure (XCUR), Pasithea Therapeutics (KTTA), Quince Therapeutics (QNCX), and Lipocine (LPCN). These companies are all part of the "pharmaceutical products" industry.

How does Psyence Biomedical compare to AEON Biopharma?

AEON Biopharma (NASDAQ:AEON) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the superior investment? We will compare the two businesses based on the strength of their media sentiment, institutional ownership, valuation, risk, analyst recommendations, earnings, dividends and profitability.

AEON Biopharma is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AEON Biopharma	N/A	N/A	-$36.63M	-$2.43	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.20

In the previous week, Psyence Biomedical had 1 more articles in the media than AEON Biopharma. MarketBeat recorded 3 mentions for Psyence Biomedical and 2 mentions for AEON Biopharma. Psyence Biomedical's average media sentiment score of 1.89 beat AEON Biopharma's score of 0.00 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
AEON Biopharma	0 Very Positive mention(s)	0 Positive mention(s)	2 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Psyence Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

AEON Biopharma has a beta of 0.66, meaning that its stock price is 34% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.78, meaning that its stock price is 78% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AEON Biopharma	0 Sell rating(s)	1 Hold rating(s)	1 Buy rating(s)	1 Strong Buy rating(s)	3.00
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Company	Net Margins	Return on Equity	Return on Assets
AEON Biopharma	N/A	N/A	-994.63%
Psyence Biomedical	N/A	N/A	N/A

22.8% of AEON Biopharma shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 9.4% of AEON Biopharma shares are held by insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a company will outperform the market over the long term.

Summary

Psyence Biomedical beats AEON Biopharma on 7 of the 12 factors compared between the two stocks.

How does Psyence Biomedical compare to Exicure?

Psyence Biomedical (NASDAQ:PBM) and Exicure (NASDAQ:XCUR) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

Exicure is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.20
Exicure	N/A	N/A	-$4.95M	-$0.77	N/A

In the previous week, Psyence Biomedical had 1 more articles in the media than Exicure. MarketBeat recorded 3 mentions for Psyence Biomedical and 2 mentions for Exicure. Psyence Biomedical's average media sentiment score of 1.89 beat Exicure's score of 0.93 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Psyence Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive
Exicure	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive

Psyence Biomedical has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Exicure has a beta of 3.62, indicating that its share price is 262% more volatile than the broader market.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Exicure	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical's return on equity of 0.00% beat Exicure's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Exicure	N/A	-138.71%	-62.76%

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 42.8% of Exicure shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 52.8% of Exicure shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Summary

Psyence Biomedical beats Exicure on 8 of the 10 factors compared between the two stocks.

How does Psyence Biomedical compare to Pasithea Therapeutics?

Psyence Biomedical (NASDAQ:PBM) and Pasithea Therapeutics (NASDAQ:KTTA) are both small-cap medical companies, but which is the superior stock? We will contrast the two companies based on the strength of their risk, earnings, institutional ownership, profitability, dividends, analyst recommendations, media sentiment and valuation.

In the previous week, Psyence Biomedical had 2 more articles in the media than Pasithea Therapeutics. MarketBeat recorded 3 mentions for Psyence Biomedical and 1 mentions for Pasithea Therapeutics. Psyence Biomedical's average media sentiment score of 1.89 beat Pasithea Therapeutics' score of 1.87 indicating that Psyence Biomedical is being referred to more favorably in the media.

Company	Overall Sentiment
Psyence Biomedical	Very Positive
Pasithea Therapeutics	Very Positive

77.4% of Psyence Biomedical shares are owned by institutional investors. Comparatively, 23.9% of Pasithea Therapeutics shares are owned by institutional investors. 3.6% of Psyence Biomedical shares are owned by insiders. Comparatively, 2.0% of Pasithea Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock will outperform the market over the long term.

Pasithea Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.20
Pasithea Therapeutics	N/A	N/A	-$20.43M	-$3.57	N/A

Psyence Biomedical has a beta of 1.78, indicating that its share price is 78% more volatile than the broader market. Comparatively, Pasithea Therapeutics has a beta of 0.22, indicating that its share price is 78% less volatile than the broader market.

Pasithea Therapeutics has a consensus target price of $3.00, indicating a potential upside of 271.75%. Given Pasithea Therapeutics' stronger consensus rating and higher possible upside, analysts plainly believe Pasithea Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00
Pasithea Therapeutics	2 Sell rating(s)	0 Hold rating(s)	1 Buy rating(s)	0 Strong Buy rating(s)	1.67

Psyence Biomedical's return on equity of 0.00% beat Pasithea Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Psyence Biomedical	N/A	N/A	N/A
Pasithea Therapeutics	N/A	-85.48%	-77.42%

Summary

Psyence Biomedical beats Pasithea Therapeutics on 10 of the 13 factors compared between the two stocks.

How does Psyence Biomedical compare to Quince Therapeutics?

Quince Therapeutics (NASDAQ:QNCX) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

In the previous week, Quince Therapeutics had 1 more articles in the media than Psyence Biomedical. MarketBeat recorded 4 mentions for Quince Therapeutics and 3 mentions for Psyence Biomedical. Psyence Biomedical's average media sentiment score of 1.89 beat Quince Therapeutics' score of 1.35 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Quince Therapeutics	0 Very Positive mention(s)	1 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Positive
Psyence Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

30.8% of Quince Therapeutics shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 20.3% of Quince Therapeutics shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Quince Therapeutics is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Quince Therapeutics	N/A	N/A	-$83.98M	-$10.62	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.20

Quince Therapeutics has a beta of 1.45, meaning that its share price is 45% more volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market.

Quince Therapeutics currently has a consensus target price of $65.00, indicating a potential upside of 5,576.86%. Given Quince Therapeutics' stronger consensus rating and higher probable upside, equities analysts plainly believe Quince Therapeutics is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Quince Therapeutics	2 Sell rating(s)	5 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.71
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Psyence Biomedical's return on equity of 0.00% beat Quince Therapeutics' return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Quince Therapeutics	N/A	-372.88%	-67.99%
Psyence Biomedical	N/A	N/A	N/A

Summary

Psyence Biomedical beats Quince Therapeutics on 8 of the 12 factors compared between the two stocks.

How does Psyence Biomedical compare to Lipocine?

Lipocine (NASDAQ:LPCN) and Psyence Biomedical (NASDAQ:PBM) are both small-cap medical companies, but which is the better investment? We will compare the two companies based on the strength of their dividends, media sentiment, risk, institutional ownership, analyst recommendations, earnings, valuation and profitability.

In the previous week, Psyence Biomedical had 1 more articles in the media than Lipocine. MarketBeat recorded 3 mentions for Psyence Biomedical and 2 mentions for Lipocine. Psyence Biomedical's average media sentiment score of 1.89 beat Lipocine's score of 0.43 indicating that Psyence Biomedical is being referred to more favorably in the news media.

Company	Very Positive	Positive	Neutral	Negative	Very Negative	Overall Sentiment
Lipocine	0 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Neutral
Psyence Biomedical	1 Very Positive mention(s)	0 Positive mention(s)	1 Neutral mention(s)	0 Negative mention(s)	0 Very Negative mention(s)	Very Positive

Lipocine has a beta of 0.5, meaning that its share price is 50% less volatile than the broader market. Comparatively, Psyence Biomedical has a beta of 1.78, meaning that its share price is 78% more volatile than the broader market.

9.1% of Lipocine shares are held by institutional investors. Comparatively, 77.4% of Psyence Biomedical shares are held by institutional investors. 6.4% of Lipocine shares are held by company insiders. Comparatively, 3.6% of Psyence Biomedical shares are held by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock is poised for long-term growth.

Psyence Biomedical has lower revenue, but higher earnings than Lipocine. Lipocine is trading at a lower price-to-earnings ratio than Psyence Biomedical, indicating that it is currently the more affordable of the two stocks.

Company	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
Lipocine	$1.98M	9.57	-$9.63M	-$1.88	N/A
Psyence Biomedical	N/A	N/A	$1.01M	$25.34	0.20

Psyence Biomedical has a net margin of 0.00% compared to Lipocine's net margin of -571.18%. Psyence Biomedical's return on equity of 0.00% beat Lipocine's return on equity.

Company	Net Margins	Return on Equity	Return on Assets
Lipocine	-571.18%	-66.70%	-59.39%
Psyence Biomedical	N/A	N/A	N/A

Lipocine currently has a consensus target price of $15.00, indicating a potential upside of 552.17%. Given Lipocine's stronger consensus rating and higher probable upside, equities analysts plainly believe Lipocine is more favorable than Psyence Biomedical.

Company	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
Lipocine	1 Sell rating(s)	1 Hold rating(s)	0 Buy rating(s)	1 Strong Buy rating(s)	2.33
Psyence Biomedical	1 Sell rating(s)	0 Hold rating(s)	0 Buy rating(s)	0 Strong Buy rating(s)	1.00

Summary

Psyence Biomedical beats Lipocine on 10 of the 15 factors compared between the two stocks.

Get Psyence Biomedical News Delivered to You Automatically

Subscribe Now

SMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy.

New MarketBeat Followers Over Time

This chart shows the number of new MarketBeat users adding PBM and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.

Media Sentiment Over Time

This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.

PBM vs. The Competition

Export

Metric	Psyence Biomedical	MED Industry	Medical Sector	NASDAQ Exchange
Market Cap	$5.14M	$3.31B	$6.23B	$12.35B
Dividend Yield	N/A	2.31%	2.80%	5.35%
P/E Ratio	0.20	18.15	20.41	25.39
Price / Sales	N/A	281.36	541.58	73.15
Price / Cash	0.46	125.29	43.26	56.33
Price / Book	0.07	6.74	9.83	6.93
Net Income	$1.01M	$24.11M	$3.56B	$333.88M
7 Day Performance	-10.29%	3.92%	0.52%	0.03%
1 Month Performance	74.13%	-2.85%	-0.71%	1.93%
1 Year Performance	-81.85%	68.91%	36.34%	33.14%

Psyence Biomedical Competitors List

Export

Company	MarketRank	Share Price	Analysts' Price Target	1Y Price Performance	Market Cap	Revenue	P/E Ratio	Employee Count	Indicator(s)
PBM Psyence Biomedical	1.7865 of 5 stars	$5.02 -0.5%	N/A	-81.7%	$5.14M	N/A	0.20	N/A	Positive News Gap Down
AEON AEON Biopharma	0.8435 of 5 stars	$0.80 -2.3%	N/A	+60.9%	$20.27M	N/A	4.45	5	News Coverage Upcoming Earnings Gap Down
XCUR Exicure	1.0391 of 5 stars	$3.18 +1.3%	N/A	-70.2%	$20.26M	$500K	N/A	50	Gap Down
KTTA Pasithea Therapeutics	2.7095 of 5 stars	$0.79 +1.2%	$3.00 +277.7%	-16.9%	$19.81M	N/A	N/A	3	Positive News Upcoming Earnings
QNCX Quince Therapeutics	2.7623 of 5 stars	$1.18 -3.3%	$65.00 +5,408.5%	-86.0%	$19.23M	N/A	N/A	60	News Coverage Positive News Earnings Report

Related Companies and Tools

Related Companies

Top 10 Stock Comparisons

This page (NASDAQ:PBM) was last updated on 5/15/2026 by MarketBeat.com Staff.

From Our Partners

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Psyence Biomedical (PBM) Competitors

PBM vs. AEON, XCUR, KTTA, QNCX, and LPCN

How does Psyence Biomedical compare to AEON Biopharma?

Summary

How does Psyence Biomedical compare to Exicure?

Summary

How does Psyence Biomedical compare to Pasithea Therapeutics?

Summary

How does Psyence Biomedical compare to Quince Therapeutics?

Summary

How does Psyence Biomedical compare to Lipocine?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Psyence Biomedical (PBM) Competitors

PBM vs. AEON, XCUR, KTTA, QNCX, and LPCN

How does Psyence Biomedical compare to AEON Biopharma?

Which has preferable valuation and earnings, AEON or PBM?

Does the media refer more to AEON or PBM?

Which has more volatility & risk, AEON or PBM?

Do analysts rate AEON or PBM?

Is AEON or PBM more profitable?

Do institutionals and insiders have more ownership in AEON or PBM?

Summary

How does Psyence Biomedical compare to Exicure?

Which has higher earnings & valuation, PBM or XCUR?

Does the media refer more to PBM or XCUR?

Which has more volatility and risk, PBM or XCUR?

Do analysts recommend PBM or XCUR?

Is PBM or XCUR more profitable?

Do institutionals and insiders believe in PBM or XCUR?

Summary

How does Psyence Biomedical compare to Pasithea Therapeutics?

Does the media refer more to PBM or KTTA?

Do institutionals and insiders believe in PBM or KTTA?

Which has higher earnings & valuation, PBM or KTTA?

Which has more volatility and risk, PBM or KTTA?

Do analysts recommend PBM or KTTA?

Is PBM or KTTA more profitable?

Summary

How does Psyence Biomedical compare to Quince Therapeutics?

Does the media prefer QNCX or PBM?

Do insiders & institutionals have more ownership in QNCX or PBM?

Which has better valuation & earnings, QNCX or PBM?

Which has more risk & volatility, QNCX or PBM?

Do analysts rate QNCX or PBM?

Is QNCX or PBM more profitable?

Summary

How does Psyence Biomedical compare to Lipocine?

Does the media prefer LPCN or PBM?

Which has more risk & volatility, LPCN or PBM?

Do insiders & institutionals have more ownership in LPCN or PBM?

Which has better valuation & earnings, LPCN or PBM?

Is LPCN or PBM more profitable?

Do analysts rate LPCN or PBM?

Summary

New MarketBeat Followers Over Time

Media Sentiment Over Time

PBM vs. The Competition

Psyence Biomedical Competitors List

Related Companies and Tools

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools